- Home
- CL vs GILD Comparison
CL vs GILD Comparison
Compare CL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CL
- GILD
- Stock Information
- Founded
- CL 1806
- GILD 1987
- Country
- CL United States
- GILD United States
- Employees
- CL N/A
- GILD N/A
- Industry
- CL Package Goods/Cosmetics
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CL Consumer Discretionary
- GILD Health Care
- Exchange
- CL Nasdaq
- GILD Nasdaq
- Market Cap
- CL 74.7B
- GILD 113.0B
- IPO Year
- CL N/A
- GILD 1992
- Fundamental
- Price
- CL $87.68
- GILD $91.00
- Analyst Decision
- CL Buy
- GILD Buy
- Analyst Count
- CL 20
- GILD 26
- Target Price
- CL $103.63
- GILD $98.17
- AVG Volume (30 Days)
- CL 4.5M
- GILD 6.1M
- Earning Date
- CL 01-31-2025
- GILD 02-11-2025
- Dividend Yield
- CL 2.29%
- GILD 3.38%
- EPS Growth
- CL 82.83
- GILD N/A
- EPS
- CL 3.48
- GILD 0.10
- Revenue
- CL $20,106,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- CL $6.82
- GILD $6.50
- Revenue Next Year
- CL $2.75
- GILD $0.36
- P/E Ratio
- CL $25.19
- GILD $937.09
- Revenue Growth
- CL 5.07
- GILD 3.31
- 52 Week Low
- CL $79.69
- GILD $62.07
- 52 Week High
- CL $109.30
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- CL 32.10
- GILD 48.04
- Support Level
- CL $85.87
- GILD $88.57
- Resistance Level
- CL $92.73
- GILD $91.43
- Average True Range (ATR)
- CL 1.15
- GILD 1.56
- MACD
- CL -0.33
- GILD -0.33
- Stochastic Oscillator
- CL 26.38
- GILD 40.64
About CL Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).